Search
Respiratory Research and Development Timeline.pdf
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Cat diabetes infographic with key facts and figures
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Animal Health partnering interests
Animal Health partnering interests
Corporate Profile
Corporate Profile
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Snacks
Explore all of the sweet and savoury snack recipes from Taking Cancer on Through Flavour here.
How mobile medical clinics tackle health equity Down Under
We support Heart of Australia to improve health in rural communities
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies